心的外傷後ストレス障害(PTSD)治療薬の世界市場2018-2022...市場調査レポートについてご紹介

【英文タイトル】Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2018-2022

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: PIPELINE LANDSCAPE
PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: MARKET SEGMENTATION BY PRODUCT
• Segmentation by product
• Comparison by product
• Antidepressants
• Anxiolytics
• Other PTSD therapeutics
• Market opportunity by product
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• PTSD therapeutics market in Americas
• PTSD therapeutics market in EMEA
• PTSD therapeutics market in APAC
• Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 13: MARKET TRENDS
• Emerging therapies for PTSD treatment
• Increasing focus on clinical research by pharmaceutical companies and institutions
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 15: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• GlaxoSmithKline
• Pfizer
• Eli Lilly and Company
• H. Lundbeck
PART 16: APPENDIX
• List of abbreviations

Exhibit 01: Parent market
Exhibit 02: Global CNS disorders therapeutics market segmentation
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Major pipeline products
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global PTSD therapeutics market – Market size and forecast 2017-2022 ($ mn)
Exhibit 10: Global PTSD therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition – Five forces 2017
Exhibit 19: Global PTSD therapeutics market – Market share 2017-2022 (%)
Exhibit 20: Comparison by product
Exhibit 21: Antidepressants market – Market size and forecast 2017-2022 ($ mn)
Exhibit 22: Antidepressants market – Year-over-year growth 2018-2022 (%)
Exhibit 23: Anxiolytics market – Market size and forecast 2017-2022 ($ mn)
Exhibit 24: Anxiolytics market – Year-over-year growth 2018-2022 (%)
Exhibit 25: Other PTSD therapeutics – Market size and forecast 2017-2022 ($ mn)
Exhibit 26: Other PTSD therapeutics – Year-over-year growth 2018-2022 (%)
Exhibit 27: Market opportunity by product
Exhibit 28: Customer landscape
Exhibit 29: Global PTSD therapeutics market – Market share by geography 2017-2022 (%)
Exhibit 30: Regional comparison
Exhibit 31: PTSD therapeutics market in Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 32: PTSD therapeutics market in Americas – Year-over-year growth 2018-2022 (%)
Exhibit 33: Top 3 countries in Americas
Exhibit 34: PTSD therapeutics market in EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 35: PTSD therapeutics market in EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 36: Top 3 countries in EMEA
Exhibit 37: PTSD therapeutics market in APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 38: PTSD therapeutics market in APAC – Year-over-year growth 2018-2022 (%)
Exhibit 39: Top 3 countries in APAC
Exhibit 40: Market opportunity
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: GlaxoSmithKline – Overview
Exhibit 47: GlaxoSmithKline – Business segments
Exhibit 48: GlaxoSmithKline – Organizational developments
Exhibit 49: GlaxoSmithKline – Geographic focus
Exhibit 50: GlaxoSmithKline – Segment focus
Exhibit 51: GlaxoSmithKline – Key offerings
Exhibit 52: GlaxoSmithKline – Key customers
Exhibit 53: Pfizer – Overview
Exhibit 54: Pfizer – Business segments
Exhibit 55: Pfizer – Organizational developments
Exhibit 56: Pfizer – Geographic focus
Exhibit 57: Pfizer – Segment focus
Exhibit 58: Pfizer – Key offerings
Exhibit 59: Pfizer – Key customers
Exhibit 60: Eli Lilly and Company – Overview
Exhibit 61: Eli Lilly and Company – Business segments
Exhibit 62: Eli Lilly and Company – Organizational developments
Exhibit 63: Eli Lilly and Company – Geographic focus
Exhibit 64: Eli Lilly and Company – Segment focus
Exhibit 65: Eli Lilly and Company – Key offerings
Exhibit 66: Eli Lilly and Company – Key customers
Exhibit 67: H. Lundbeck – Overview
Exhibit 68: H. Lundbeck – Business segments
Exhibit 69: H. Lundbeck – Organizational developments
Exhibit 70: H. Lundbeck – Geographic focus
Exhibit 71: H. Lundbeck – Segment focus
Exhibit 72: H. Lundbeck – Key offerings
Exhibit 73: H. Lundbeck – Key customers


【レポート販売概要】

■ タイトル:心的外傷後ストレス障害(PTSD)治療薬の世界市場2018-2022
■ 英文:Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2018-2022
■ 発行日:2018年3月22日
■ 調査会社:Technavio
■ 商品コード:IRTNTR21624
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。